Topics:

All Content

In patients with non–clear cell RCC, PD-L1 positivity is associated with worse clinical outcomes, including a shorter overall survival and time to recurrence.

A new study found that the androgen receptor splice variant 7 is associated with resistance to two therapies for metastatic castration-resistant prostate cancer.

Maintenance therapy with the oral agent pazopanib improved progression free survival (PFS) by a median of 5.6 months in patients with advanced ovarian cancer but did not impact overall survival, according to the results of a phase III ran

In the largest single prospective trial to date evaluating a possible link between prostate cancer and male pattern baldness, researchers found that men who had moderate baldness in the front and crown of the head at age 45 had up to a 40

Oncologists should be experts at farewells. I often write a note of condolence if I have not made personal contact with the patient or family close to the time of death.

In this interview we discuss the American Society of Clinical Oncology’s (ASCO) health information and patient record initiative called CancerLinQ.

Multiple myeloma patients may already suffer from sensory deficits prior to treatment, likely due to disease-related decreases in peripheral innervation density.

HER2-positive breast cancer patients treated with targeted therapy and chemo were less likely to have a pathologic complete response if they had a PIK3CA mutation.

Results of a new study show that cancer rates among children and adolescents are stable, but rates of certain cancers such as renal carcinomas are increasing.

This review will focus largely on the effects of systemic cytotoxic treatment on cognitive function, reflecting what has been most extensively studied in the literature.

Pages

By clicking Accept, you agree to become a member of the UBM Medica Community.